Burkholderia cepacia in cystic fibrosis children and adolescents: overall survival and immune alterations.
| Autor: | Shmarina G; Research Centre for Medical Genetics, Moscow, Russia.; Peoples' Friendship University of Russia (RUDN University), Moscow, Russia., Pukhalskaya D; Research Centre for Medical Genetics, Moscow, Russia., Shmarin V; Research Centre for Medical Genetics, Moscow, Russia.; First Moscow State Medical University, Moscow, Russia., Semykin S; Russian Clinical Children's Hospital, a separate structural unit of the Russian National Research Medical University, Moscow, Russia., Avakyan L; Russian Clinical Children's Hospital, a separate structural unit of the Russian National Research Medical University, Moscow, Russia., Krasovsky S; Pulmonary Research Institute, Moscow, Russia., Goryainova A; Russian Clinical Children's Hospital, a separate structural unit of the Russian National Research Medical University, Moscow, Russia., Kostyuk S; Research Centre for Medical Genetics, Moscow, Russia., Zinchenko R; Research Centre for Medical Genetics, Moscow, Russia., Kashirskaya N; Research Centre for Medical Genetics, Moscow, Russia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2024 Jul 01; Vol. 14, pp. 1374318. Date of Electronic Publication: 2024 Jul 01 (Print Publication: 2024). |
| DOI: | 10.3389/fcimb.2024.1374318 |
| Abstrakt: | Background: In current literature there are only scarce data on the host inflammatory response during Burkholderia cepacia complex (Bcc) persistence. The primary objective of the present research was to carry out cross-sectional analyses of biomarkers and evaluate disease progression in cystic fibrosis (CF) patients with chronic Bcc infection and pathogen-free ones. The secondary aim was to assess prospectively overall survival of the study participants during up to 8 years of follow-up. Methods: The study included 116 paediatric patients with CF; 47 CF patients were chronically infected with Bcc, and 69 individuals were Bcc free. Plasma and sputum biomarkers (neutrophil elastase, MMP-8, MMP-9, MMP-12, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, IL-22, IL-23, IL-17, IFN-γ, TGFβ Results: Bcc infected patients did not differ from Bcc free ones in demographic and clinical parameters, but demonstrated an increased rate of glucose metabolism disturbances and survival disadvantage during prolong follow-up period. Biomarkers analyses revealed elevated TNF-α and reduced IL-17F levels in sputum samples of Bcc infected patients. These patients also demonstrated improvement of peripheral blood lymphocyte sensitivity to steroid treatment and reduction in plasma pro-inflammatory (IL-17F and IL-18) and anti-inflammatory (TGFβ1 and IL-10) cytokine concentrations. Conclusions: Reduction in IL-17F levels may have several important consequences including increase in steroid sensitivity and glycemic control disturbances. Further investigations are needed to clarify the role of IL-17 cytokines in CF complication development. Low plasma TGFβ1 and IL-10 levels in Bcc infected group may be a sign of subverted activity of regulatory T cells. Such immune alterations may be one of the factors contributing to the development of the cepacia syndrome. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Shmarina, Pukhalskaya, Shmarin, Semykin, Avakyan, Krasovsky, Goryainova, Kostyuk, Zinchenko and Kashirskaya.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|